For example, suppression of CD4+ T-cell activation by AML cells at onset is strongly associated with unfavorable outcomes in AML patients receiving standard chemotherapy, closely related to the CIITA (the master regulator of MHC class II expression), CD200 and MRC1 (Macrophage mannose receptor 1) expression in AML cells (10). Here, MRC1 is linked to acute myeloid leukemia.